- Vectura, an inhaled product formulation, device design and development business, has confirmed its revenues are in line with its expectations for the full year.

Growth in revenues continues to be driven by Vectura's key inhaled marketed products including flutiform and Ultibro.

Vectura's chief executive officer, James Ward-Lilley, said: "We have made a good start to the year and see the performance from our in-market business tracking as expected. We are making significant progress with our pipeline with a broad series of news flow anticipated for the rest of 2018, including our novel partnered projects (Ablynx ALX-0171), generic projects, late stage nebulised studies (VR647 Phase II, VR475 Phase III) and further Vectura enhanced programmes."

At 9:03am: [LON:VEC] Vectura Group PLC share price was +0.2p at 86p

Story provided by